Liver NK cell therapy for preventing infection after liver transplant

Adoptive immunotherapy using donor liver graft derived natural killer (NK) cells for preventing severe infection after liver transplantation

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTa060190036

Enrollment

Registered

2020-02-27

Start date

2016-03-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Decompensated liver cirrhosis patients who will receive liver transplantation

Interventions

Single infusion of donor liver graft derived NK cells to the recipient 3 days after liver trasplantation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Recipient 1) decompensated liver cirrhotic patients who will receive liver transplantation 2) 20 years old or older 3) written informed consent from patients or legal guardian

Exclusion criteria

Exclusion criteria: 1) patients who will receive re-transplantation 2) patients who will receive deceased donor liver transplantation 3) patients whom the researchers decided as inappropriate to be participated

Design outcomes

Primary

Measure	Time frame
Incidence of blood stream infection during one month after liver transplantation	—

Secondary

Measure	Time frame
1. Overall survival (6 months, 1 and 3 years) 2. Effect on immunological reaponse after liver transplantation Evaluation by CFSE-MLR (1, 2, 3, and 4 weeks after LT) Examination of DSA (donor specific antibody) (annually) 3. Incidence of recurrence of hepatocellular carcinoma and de novo malignancy 4. Incidence of other infectious disease 5. Safety evaluation	—

Countries

Japan

Contacts

Public ContactAyaka Morikawa

Hiroshima University

morik@hiroshima-u.ac.jp+81-82-257-5220

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026